[go: up one dir, main page]

YU68199A - Farmaceutske formulacije koje sadrže vorikonazol - Google Patents

Farmaceutske formulacije koje sadrže vorikonazol

Info

Publication number
YU68199A
YU68199A YU68199A YU68199A YU68199A YU 68199 A YU68199 A YU 68199A YU 68199 A YU68199 A YU 68199A YU 68199 A YU68199 A YU 68199A YU 68199 A YU68199 A YU 68199A
Authority
YU
Yugoslavia
Prior art keywords
pharmaceutical formulations
formulations containing
voriconazole
containing voriconazole
pharmaceutically acceptable
Prior art date
Application number
YU68199A
Other languages
English (en)
Inventor
Valerie Denise Harding
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU68199(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU68199A publication Critical patent/YU68199A/sh
Publication of RS49633B publication Critical patent/RS49633B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Pronalazak obezbedjuje farmaceutsku formulaciju koja obuhvata vorikonazol ili njegov farmaceutski prihvatljiv derivat i ciklodekstrinski derivat formule I: gde R1a-g, R2a-g i R3a-g svaki nezavisno predstavlja OH ili O(CH2)4SO3H; uz predpostavku da bar jedan od R1a-g predstavlja O(CH2)4SO3H; ili njegovu farmaceutski prihvatljivu so.[The invention provides a pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a cyclodextrin derivative of formula (I), wherein R1a-g, R2a-g and R3a-g independently represent OH or O(CH2)4SO3H; or a pharmaceutically acceptable salt thereof.
YUP-681/99A 1997-06-21 1998-06-02 Farmaceutske formulacije koje sadrže vorikonazol RS49633B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
YU68199A true YU68199A (sh) 2002-06-19
RS49633B RS49633B (sr) 2007-08-03

Family

ID=10814734

Country Status (48)

Country Link
US (1) US6632803B1 (sh)
EP (1) EP1001813B8 (sh)
JP (2) JP2000513029A (sh)
KR (1) KR100372988B1 (sh)
CN (1) CN1125653C (sh)
AP (1) AP912A (sh)
AR (1) AR015900A1 (sh)
AT (1) ATE238812T1 (sh)
AU (1) AU724799B2 (sh)
BG (1) BG64584B1 (sh)
BR (1) BRPI9809468B8 (sh)
CA (1) CA2295035C (sh)
CO (1) CO4940450A1 (sh)
CZ (1) CZ289570B6 (sh)
DE (1) DE69814091T2 (sh)
DK (1) DK1001813T3 (sh)
DZ (1) DZ2523A1 (sh)
EA (1) EA001924B1 (sh)
EG (1) EG23910A (sh)
ES (1) ES2195355T3 (sh)
GB (1) GB9713149D0 (sh)
HK (1) HK1027966A1 (sh)
HR (1) HRP980341B1 (sh)
HU (1) HU228338B1 (sh)
ID (1) ID22939A (sh)
IL (1) IL132918A (sh)
IS (1) IS2004B (sh)
MA (1) MA26508A1 (sh)
ME (1) ME00907B (sh)
MY (1) MY118151A (sh)
NO (1) NO313125B1 (sh)
NZ (1) NZ501066A (sh)
OA (1) OA11232A (sh)
PA (1) PA8453201A1 (sh)
PE (1) PE84899A1 (sh)
PL (1) PL191295B1 (sh)
PT (1) PT1001813E (sh)
RS (1) RS49633B (sh)
SA (1) SA98190159B1 (sh)
SI (1) SI1001813T1 (sh)
SK (1) SK282946B6 (sh)
TN (1) TNSN98090A1 (sh)
TR (1) TR199903191T2 (sh)
TW (1) TW406023B (sh)
UA (1) UA57083C2 (sh)
UY (1) UY25055A1 (sh)
WO (1) WO1998058677A1 (sh)
ZA (1) ZA985364B (sh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
EP1542668B1 (en) * 2002-08-20 2009-04-15 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
AU2004296863B2 (en) * 2003-12-08 2008-12-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达（北京）医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (en) * 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
WO2009137611A2 (en) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Treatment of pulmonary fungal infection with voriconazole via inhalation
EP2303265B1 (en) * 2008-06-06 2014-12-10 Glenmark Pharmaceuticals Limited Stable topical formulation comprising voriconazole
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药系统
EP2349313A4 (en) 2008-10-21 2012-08-29 Onyx Therapeutics Inc COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
ES2573982T3 (es) 2009-08-19 2016-06-13 Ratiopharm Gmbh Proceso para la producción de coevaporados y complejos que comprenden voriconazol y ciclodextrina
WO2011064558A2 (en) 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
KR101834024B1 (ko) 2010-06-29 2018-03-02 머크 샤프 앤드 돔 코포레이션 치환된 베타―시클로덱스트린에 의해 안정화된 포사코나졸 정맥내 용액 제제
EP2409699B1 (en) * 2010-07-23 2014-04-30 Combino Pharm, S.L. Stable compositions of voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
EP2720723B1 (en) 2011-06-15 2018-04-11 Synthon BV Stabilized voriconazole composition
EP2561863A1 (en) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmaceutical compositions comprising voriconazole
WO2013109421A1 (en) * 2012-01-05 2013-07-25 Guilford Frederick Timothy Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
KR20240119191A (ko) 2012-05-08 2024-08-06 오닉스 세라퓨틱스, 인크. 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
IN2014MN02236A (sh) 2012-05-11 2015-07-24 Cipla Ltd
ES2780363T3 (es) 2013-01-11 2020-08-25 Xellia Pharmaceuticals Aps Complejos de inclusión de voriconazol
WO2014182368A2 (en) 2013-03-14 2014-11-13 Fresenius Kabi Usa, Llc Voriconazole formulations
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术（石家庄）有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
CA3043979A1 (en) 2016-11-18 2018-05-24 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
WO2018149359A1 (zh) * 2017-02-17 2018-08-23 武汉朗来科技发展有限公司 三氮唑抗菌衍生物、其药物组合物和用途
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9512961D0 (en) * 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
SA98190159B1 (ar) 2005-12-21
PE84899A1 (es) 1999-09-17
PA8453201A1 (es) 2000-05-24
US6632803B1 (en) 2003-10-14
MY118151A (en) 2004-09-30
SI1001813T1 (en) 2004-02-29
JP5089004B2 (ja) 2012-12-05
UA57083C2 (uk) 2003-06-16
IS5248A (is) 1999-11-15
HU228338B1 (en) 2013-03-28
JP2000513029A (ja) 2000-10-03
DE69814091D1 (de) 2003-06-05
ATE238812T1 (de) 2003-05-15
PL191295B1 (pl) 2006-04-28
DZ2523A1 (fr) 2003-02-01
TR199903191T2 (xx) 2000-09-21
MA26508A1 (fr) 2004-12-20
AR015900A1 (es) 2001-05-30
WO1998058677A1 (en) 1998-12-30
CN1125653C (zh) 2003-10-29
IS2004B (is) 2005-04-15
UY25055A1 (es) 2000-12-29
ES2195355T3 (es) 2003-12-01
ID22939A (id) 1999-12-16
KR20010014006A (ko) 2001-02-26
BR9809468B1 (pt) 2013-11-12
EP1001813B8 (en) 2014-02-12
NZ501066A (en) 2001-01-26
DE69814091T2 (de) 2004-01-22
HRP980341A2 (en) 1999-02-28
EA199900937A1 (ru) 2000-08-28
IL132918A (en) 2001-09-13
GB9713149D0 (en) 1997-08-27
AU8110498A (en) 1999-01-04
CA2295035C (en) 2005-04-19
EA001924B1 (ru) 2001-10-22
EP1001813A1 (en) 2000-05-24
BR9809468A (pt) 2000-06-20
IL132918A0 (en) 2001-03-19
AP9801268A0 (en) 1998-06-30
KR100372988B1 (ko) 2003-02-25
ME00907B (me) 2007-08-03
CZ409699A3 (cs) 2000-02-16
AP912A (en) 2001-12-08
PL337692A1 (en) 2000-08-28
BG103882A (en) 2000-07-31
NO995565L (no) 1999-11-30
BG64584B1 (bg) 2005-08-31
HUP0003323A3 (en) 2002-01-28
SK159399A3 (en) 2000-06-12
JP2002332234A (ja) 2002-11-22
PT1001813E (pt) 2003-07-31
TW406023B (en) 2000-09-21
HUP0003323A2 (hu) 2001-06-28
EP1001813B1 (en) 2003-05-02
CZ289570B6 (cs) 2002-02-13
RS49633B (sr) 2007-08-03
CO4940450A1 (es) 2000-07-24
DK1001813T3 (da) 2003-07-28
NO313125B1 (no) 2002-08-19
CA2295035A1 (en) 1998-12-30
HRP980341B1 (en) 2001-12-31
AU724799B2 (en) 2000-09-28
SK282946B6 (sk) 2003-01-09
BRPI9809468B8 (pt) 2022-01-18
CN1261287A (zh) 2000-07-26
HK1027966A1 (en) 2001-02-02
EG23910A (en) 2007-12-30
NO995565D0 (no) 1999-11-12
ZA985364B (en) 1999-12-20
TNSN98090A1 (fr) 2005-03-15
OA11232A (en) 2003-05-26

Similar Documents

Publication Publication Date Title
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
DE60116761D1 (en) Adamantanderivate
TR199901077A2 (en) �spen�iyari form�lasyonlar.
PL367682A1 (en) Dolastatin 10 derivatives
EP1033981A4 (en) FORMULATIONS AND METHODS FOR REDUCING THE TOXICITY OF ANTINEOPLASTIC AGENTS
IL133397A0 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
SE9904505D0 (sv) Novel compounds
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
MXPA03010761A (es) Combinaciones farmaceuticas.
AU3868997A (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
MX9601994A (es) Profarmacos de derivados de paclitaxel.
GB9907571D0 (en) Compounds
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
GEP20063719B (en) Prevention of Migraine Recurrence
AU7270798A (en) Antithrombotic agents
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
YU10599A (sh) Amorfni benzotiofeni, postupak dobijanja istih i njihova farmaceutska formulacija
AU7296696A (en) Deodorising formulations containing cationic biopolymers, aluminium chlorhydrate and esterase inhibitors
AU1469097A (en) Pharmaceutical compounds
GEP20043377B (en) Pharmaceutical Complex
MXPA04003738A (es) Composiciones farmaceuticas que contienen macrolidos.
ES2149691A1 (es) 2-4-[4-(4,5-dicloro-2metilimidazol-1-il)butil]-1-piperacinil -5-fluoropirimidina, su preparacion y su utilizacion terapeutica.
ES2062940A1 (es) Agente gastrocinetico, proceso para su preparacion y composiciones farmaceuticas que lo contengan.
ECSP982538A (es) Formulaciones farmaceuticas que contienen variconazol